Last reviewed · How we verify
IGE-2
At a glance
| Generic name | IGE-2 |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study
- A Study To Assess The Safety And Tolerability Of Different Doses Of PF-06444753 And PF-06444752 In Subjects With Allergic Rhinitis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IGE-2 CI brief — competitive landscape report
- IGE-2 updates RSS · CI watch RSS
- Pfizer portfolio CI